DHFR is an attractive pharmaceutical target for inhibition due to its pivotal role in DNA precursor (thymine) synthesis. Trimethoprim, an antibiotic, inhibits bacterial DHFR while methotrexate, a chemotherapy agent, inhibits mammalian DHFR. However, resistance has developed against some drugs, as a result of mutational changes in DHFR itself.
DHFR is an attractive pharmaceutical target for inhibition due to its pivotal role in DNA precursor (thymine) synthesis Trimethoprim an antibiotic inhibits bacterial DHFR while methotrexate a chemotherapy agent inhibits mammalian DHFR However resistance has developed against some drugs as a result of mutational changes in DHFR itself